If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Donald Trump will put the interests of corporate America first and demand that the NHS pays higher prices for US drugs in a free-trade deal with the UK, the outgoing British ambassador to Washington said.
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
India and Indonesia are set to launch negotiations for a Comprehensive Economic Cooperation Agreement (CECA) to cover economic cooperation while trading in goods, services, and investments.
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
Mexico’s government said progress was being made toward revising a new North American trade pact that will sharply reduce protections for biologic drugs.
Generic versions of biologic drugs could come to market faster.
There are two solutions to this impending problem, which most political parties could agree to if they are truly committed to protecting the NHS.
Trading away our health: How trade and investment rules put corporate rights ahead of public health.
A Free Trade Agreement with the US will likely result in the amendment of the Patents Act, which could impact the Indian pharma industry.
The National Farmers Union says the new deal’s extended patent protection for new pharmaceuticals must be reduced so that less expensive generic versions of new drugs can be available to consumers sooner.
The mutual recognition agreement for inspections of manufacturing sites for human medicines in their respective territories can make it faster and less costly for both sides to bring medicines to the market.
Intellectual property barriers, which would hinder access to affordable medicines, have supposedly been removed from the draft RCEP free-trade agreement (FTA).
Three harmful provisions concerning pharmaceuticals and agriculture which were part of the RCEP have been withdrawn.
FTA Watch would like to urge the Thai negotiation team for the RCEP to have a
strong position to reject proposals on Intellectual Property Enforcement chapter.
US Democrats fear higher drug prices, trying to change text of trade deal
These practises open the door to Big Pharma companies and disastrous private health companies.
African governments must act immediately to address the AfCFTA’s potential negative implications for Africans’ health.
In its latest report on foreign trade barriers, the USTR, prompted by the pharmaceutical industry, takes aim at the pharmaceutical pricing and reimbursement policies in the European Union.